Dr. Erle Robertson, PhD


Dr. Erle Robertson is a Professor at the University of Pennsylvania School of Medicine. He holds appointments in the Departments of Microbiology and Radiation Oncology. He is also the director of the Tumor Virology Training Program at the Abramson Cancer Center.

Dr. Robertson holds a Ph.D. in Microbiology and Molecular Genetics from Wayne State University, an Honorary Masters from the University of Pennsylvania, and a B.S. in Microbiology from Howard University. He received his post-doctoral training at Harvard Medical School and Brigham and Women’s Hospital.

Francis Humann, MBA

President & CEO

Francis Humann joined OncoViRx as President & CEO in mid-2015. Mr. Humann has over 18 years of experience leading a broad range of pharmaceutical product/program teams. Prior to joining OncoViRx, Mr. Humann was the Senior Director of New Product Marketing at Ikaria, a specialty pharmaceutical company that was purchased by Mallinckrodt Pharmaceuticals. In this role, Mr. Humann was led several global commercial programs that ranged from preclinical to phase III, and was actively involved in developing the programs’ clinical development strategies. Prior to Ikaria, Mr. Humann held multiple senior commercial roles at Wyeth/Pfizer and Abbott Laboratories.

Mr. Humann holds an MBA from Columbia University.

Blake Tomkinson, PhD

Vice President of Discovery

Blake Tomkinson, PhD has over 20 years in the biotechnology and pharmaceutical industry with experience in virology, oncology and immunology in both small and large companies. Dr. Tomkinson has extensive experience as a program leader, leading the research and clinical development of small molecule, peptides and monoclonal antibody programs, responsible for formulating and executing the global strategy from Phase I to pivotal studies. His research and clinical development knowledge is complemented with a MBA and business development search and evaluation experience in oncology, focused on hematology malignancies and immuno-oncology.

Dr. Tomkinson received his PhD in Immunology from the University of Massachusetts Medical School, followed by post-doctoral research in molecular biology at Brigham and Women’s Hospital and Harvard Medical School. He received his MBA from the University of Colorado, Denver.

Lisa Wisniewski, PhD

Senior R&D Advisor

Lisa Wisniewski, PhD is the President of S3B Consulting and a proven drug development executive and thought leader. Dr. Wisniewski brings over 20 years of global experience driving the development and execution of pharmaceutical strategy, and leading teams and transformations that have delivered significant results in multiple therapeutic areas for companies such as Celgene, Novartis Oncology, and Chiron. Her scientific, regulatory, operational, and business experience uniquely positions her to assess, develop, and optimize pharmaceutical strategy.

Dr. Wisniewski received her BS from University of Illinois, and her MS and PhD from North Carolina State University, where she graduated Xi Sigma Pi and Sigma Xi, respectively. Following her PhD, she completed a post-doctorate at Washington University in St Louis.

Pedram Alaedini, MBA

Senior CMC & Manufacturing Advisor

Pedram Alaedini has 20 years of experience as a life science industry executive in pharmaceutical, biotechnology, and medical device industries. His broad range of expertise includes product development and technology transfer, plant management and manufacturing, engineering and technical services, operational start-ups, regulatory compliance, business development, and private equity. Mr. Alaedini has held senior level positions at American and European life science companies such as Schering-Plough, Bristol-Myers Squibb, and Novartis in addition to generic manufactures, contract service organizations, and consulting firms in the US, Europe, South America, and Asia.

Mr. Alaedini is a chemical engineer with an MBA in operations management and holds a six sigma black belt.

Betty Holland, MS

Senior Regulatory Advisor

Betty Holland has 25 years of experience in regulatory affairs in the pharmaceutical and biotechnology industries where she has successfully led teams in the development and implementation of regulatory strategy for investigational agents and marketed products in both large (Hoffmann-La Roche, Inc.) and small (Reata Pharmaceuticals, Inc. and Tanox, Inc.) companies. Her global regulatory experience includes direction of clinical and CMC regulatory activities, development of investigational, original and supplemental marketing applications, pediatric exclusivity applications, risk evaluation and mitigation strategies, and FDA advisory committee meeting presentations. Ms. Holland’s background also includes experience in multi-corporation joint development projects, and expertise in project management and scientific writing.

Ms. Holland received a BS in chemistry from Iowa State University and an MS in organic chemistry from Purdue University.